Jefferies Group Increases Cubist Pharmaceuticals Price Target to $85.00 (CBST)
Equities research analysts at Jefferies Group raised their price objective on shares of Cubist Pharmaceuticals (NASDAQ:CBST) from $82.00 to $85.00 in a research note issued to investors on Tuesday, Stock Ratings Network reports. Jefferies Group’s price target points to a potential upside of 13.68% from the company’s current price.
Shares of Cubist Pharmaceuticals (NASDAQ:CBST) traded up 2.13% during mid-day trading on Tuesday, hitting $74.77. The stock had a trading volume of 1,733,213 shares. Cubist Pharmaceuticals has a 1-year low of $40.44 and a 1-year high of $74.80. The stock’s 50-day moving average is $67.05 and its 200-day moving average is $63.05. The company has a market cap of $5.537 billion and a price-to-earnings ratio of 190.16.
In other Cubist Pharmaceuticals news, COO Robert J. Perez sold 10,000 shares of Cubist Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $72.95, for a total value of $729,500.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
CBST has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note to investors on Friday, December 27th. They now have a $70.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Cubist Pharmaceuticals from $78.00 to $82.00 in a research note to investors on Friday, December 20th. They now have an “outperform” rating on the stock. Finally, analysts at Cantor Fitzgerald raised their price target on shares of Cubist Pharmaceuticals from $63.00 to $65.00 in a research note to investors on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $68.27.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.